Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from IBS with diarrhea; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD. The company pipeline products also include olinciguat, an oral and once-daily vascular sGC stimulator, which is in Phase II trials for the treatment of patients suffering from sickle cell diseases; praliciguat, an oral, once daily systemic sGC stimulator that is in Phase II trials for the treatment of heart failure and for diabetic nephropathy; IW 6463, a central nervous system penetrant oral sGC stimulator in clinical development for serious neurodegenerative diseases; and two organ targeted programs for the treatment of liver and lung. Ironwood Pharmaceuticals, Inc. has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal (GI) conditions in North America, China, Hong Kong, Macau, and Japan, as well as a license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in Japan. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone617-621-7722
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$346.64 million
Profitability
Miscellaneous
Employees515
Next Earnings Date5/2/2019 (Confirmed)
OptionableOptionable
Ironwood Pharmaceuticals (NASDAQ:IRWD) Frequently Asked Questions
What is Ironwood Pharmaceuticals' stock symbol?
Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."
How were Ironwood Pharmaceuticals' earnings last quarter?
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced its quarterly earnings results on Wednesday, February, 13th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.15. The biotechnology company earned $130.70 million during the quarter, compared to analysts' expectations of $96.57 million. The firm's revenue for the quarter was up 38.7% on a year-over-year basis. During the same period last year, the company earned ($0.14) EPS. View Ironwood Pharmaceuticals' Earnings History.
When is Ironwood Pharmaceuticals' next earnings date?
How can I listen to Ironwood Pharmaceuticals' earnings call?
Ironwood Pharmaceuticals will be holding an earnings conference call on Thursday, May 2nd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8663934306.
What guidance has Ironwood Pharmaceuticals issued on next quarter's earnings?
Ironwood Pharmaceuticals updated its FY 2019 earnings guidance on Wednesday, February, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $370-390 million, compared to the consensus revenue estimate of $377.33 million.
What price target have analysts set for IRWD?
11 equities research analysts have issued 12 month target prices for Ironwood Pharmaceuticals' stock. Their predictions range from $13.00 to $20.00. On average, they anticipate Ironwood Pharmaceuticals' share price to reach $16.50 in the next year. This suggests a possible upside of 36.4% from the stock's current price. View Analyst Price Targets for Ironwood Pharmaceuticals.
What is the consensus analysts' recommendation for Ironwood Pharmaceuticals?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ironwood Pharmaceuticals in the last year. There are currently 7 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ironwood Pharmaceuticals.
Has Ironwood Pharmaceuticals been receiving favorable news coverage?
Media coverage about IRWD stock has been trending somewhat positive on Friday, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Ironwood Pharmaceuticals earned a coverage optimism score of 1.8 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the company's share price in the next few days.
Who are some of Ironwood Pharmaceuticals' key competitors?
Some companies that are related to Ironwood Pharmaceuticals include Jazz Pharmaceuticals (JAZZ), Beigene (BGNE), Loxo Oncology (LOXO), Dr.Reddy's Laboratories (RDY), Perrigo (PRGO), Catalent (CTLT), Amarin (AMRN), GALAPAGOS NV/S (GLPG), Nektar Therapeutics (NKTR), Alkermes (ALKS), Array Biopharma (ARRY), GW Pharmaceuticals PLC- (GWPH), Horizon Pharma (HZNP), Ascendis Pharma A/S (ASND) and United Therapeutics (UTHR).
What other stocks do shareholders of Ironwood Pharmaceuticals own?
Who are Ironwood Pharmaceuticals' key executives?
Ironwood Pharmaceuticals' management team includes the folowing people:
- Dr. Peter M. Hecht, Co-Founder, CEO & Director (Age 55)
- Mr. Thomas A. McCourt, Pres (Age 62)
- Ms. Gina R. Consylman CPA, CFO, Sr. VP & Treasurer (Age 46)
- Ms. Halley E. Gilbert, Sr. VP, Chief Legal Officer & Sec. (Age 49)
- Dr. Christopher I. Wright, Chief Devel. Officer & Sr. VP of Global Devel.
Who are Ironwood Pharmaceuticals' major shareholders?
Ironwood Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Tibra Equities Europe Ltd (0.04%), Los Angeles Capital Management & Equity Research Inc. (0.03%), First Manhattan Co. (0.03%) and BNP Paribas Arbitrage SA (0.02%). Company insiders that own Ironwood Pharmaceuticals stock include Gina Consylman, Halley E Gilbert, Julie Mchugh, Lawrence S Olanoff, Mark G Currie, Peter M Hecht and Thomas A Mccourt. View Institutional Ownership Trends for Ironwood Pharmaceuticals.
Which institutional investors are buying Ironwood Pharmaceuticals stock?
How do I buy shares of Ironwood Pharmaceuticals?
Shares of IRWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ironwood Pharmaceuticals' stock price today?
One share of IRWD stock can currently be purchased for approximately $12.10.
How big of a company is Ironwood Pharmaceuticals?
Ironwood Pharmaceuticals has a market capitalization of $1.87 billion and generates $346.64 million in revenue each year. The biotechnology company earns $-282,370,000.00 in net income (profit) each year or ($0.95) on an earnings per share basis. Ironwood Pharmaceuticals employs 515 workers across the globe.
What is Ironwood Pharmaceuticals' official website?
How can I contact Ironwood Pharmaceuticals?
Ironwood Pharmaceuticals' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-621-7722 or via email at [email protected]
MarketBeat Community Rating for Ironwood Pharmaceuticals (NASDAQ IRWD)
MarketBeat's community ratings are surveys of what our community members think about Ironwood Pharmaceuticals and other stocks. Vote "Outperform" if you believe IRWD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRWD will underperform the S&P 500 over the long term. You may vote once every thirty days.
